🇺🇸 FDA
Company

Xilio

Xilio Therapeutics

XLO pharma USA

Quick answer

Xilio is a pharma company (XLO) headquartered in WALTHAM, MA, USA with 3 tracked pipeline programs.

Pipeline (3)

project

XTX202

Advanced Solid Tumor

Phase 2 · small_molecule · completed

1 trials project

XTX301

Advanced Solid Tumor

Phase 2 · small_molecule · active

1 trials project

vilastobart (XTX101)

Advanced Solid Tumor

Phase 2 · small_molecule · active

1 trials

Patents (7)

patent

US 12384845

Activatable masked anti-CTLA4 binding proteins

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12280120

Tumor-specific cleavable linkers

Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11866476

Masked IL-2-Fc fusion polypeptides

Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11827686

Masked cytokine polypeptides

Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11827685

Masked cytokine polypeptides

Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11718655

Masked interleukin-12 polypeptides

Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11053294

Masked cytokine polypeptides

Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)